Bryan, Garnier & Co acts as Joint Lead Manager and Joint Bookrunner of DBV $133m IPO on NASDAQ.

Paris – New York, October 23rd, 2014 – Bryan, Garnier & Co, the pan-European investment bank for growth companies, announces the successful Initial Public Offering of DBV Technologies on the NASDAQ stock exchange (under the ticker symbol “DBVT”) with a global offering of $133m. Bryan, Garnier & Co acted as joint lead manager and joint bookrunner with Citi and Leerink.

The IPO of DBV Technologies consisted of a global offering of 2,673,641 new ordinary shares, of which 2,138,913 ordinary shares in the form of 4,277,826 American Depositary Shares, or ADSs, at a price to the public of $21.6359 per ADS, and 534,728 ordinary shares for €34.00 per share. As a result of significant oversubscription, the over-allotment option representing 15% additional shares was exercised. The closing of the US offering and the international registered private placement will be conditional on each other and is expected to occur on October 24th, 2014, subject to customary closing conditions.

The ADSs are traded on the NASDAQ Global Select Market under the symbol “DBVT” and the ordinary shares on the Euronext Paris under the symbol “DBV.” On the first day of trading, ADS closed at $22.90, or a 5.8% increase on the placement price of $21.64.

DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies – a major public health issue that has been increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, worldwide-patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus considerably lowering the risk of a systemic, allergic reaction in the event of accidental exposure.

Hervé Ronin, Managing Director Healthcare, said: “DBV Technologies exemplifies the high growth potential healthcare companies Bryan Garnier & Co aims to accompany in their various corporate finance needs. This successful and visible transaction confirms our expertise in the healthcare and biotech space as well as our ability to bookrun complex cross-border transactions with the US. Bryan Garnier has completed 11 IPOs and secondary offerings raising more than €500m of capital with European and American institutions since the beginning of the year.”

Cédric Moreau, Director ECM Healthcare, added: “This transaction was one of the most ambitious IPOs given its size and its cross border nature and its technical challenges. It is the first in more than a decade. The global offering was strongly oversubscribed in both Europe and the US in the context of a volatile and complex ECM environment. This large placement highlights that investors strongly believe in the DBV’s Viaskin proprietary platform, which has the potential to become a revolution in the field of immunotherapy, especially for food allergies. We expect this success to improve investors’ sentiment on the French biotech industry where a number of key catalysts and possible take-outs are expected into 2015.”

For more information, please contact:

Hervé Ronin

Managing Director – Healthcare Corporate Finance

hronin@bryangarnier.com | + 33 156687522

Cédric Moreau

Director – Healthcare Equity Capital Markets

cmoreau@bryangarnier.com | + 33 156687565

Christian Finan

Director – Equity Capital Markets

cfinan@bryangarnier.com | + 33 156687530

About DBV Technologies

DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies – a major public health issue that is constantly increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, worldwide-patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus considerably lowers the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products: Viaskin® Peanut and Viaskin® Milk. The clinical development programme for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration.

DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345).

For more information on DBV Technologies, please visit our website: www.dbv-technologies.com